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Abstract
Hirschsprung disease (HSCR, OMIM 142623) is a developmental disorder characterized by the absence of ganglion cells
along variable lengths of the distal gastrointestinal tract, which results in tonic contraction of the aganglionic gut segment
and functional intestinal obstruction. The RET proto-oncogene is the major gene for HSCR with differential contributions of
its rare and common, coding and noncoding mutations to the multifactorial nature of this pathology. Many other genes
have been described to be associated with the pathology, as NRG1 gene (8p12), encoding neuregulin 1, which is implicated
in the development of the enteric nervous system (ENS), and seems to contribute by both common and rare variants. Here
we present the results of a comprehensive analysis of the NRG1 gene in the context of the disease in a series of 207 Spanish
HSCR patients, by both mutational screening of its coding sequence and evaluation of 3 common tag SNPs as low
penetrance susceptibility factors, finding some potentially damaging variants which we have functionally characterized. All
of them were found to be associated with a significant reduction of the normal NRG1 protein levels. The fact that those
mutations analyzed alter NRG1 protein would suggest that they would be related with HSCR disease not only in Chinese but
also in a Caucasian population, which reinforces the implication of NRG1 gene in this pathology.
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Introduction
Hirschsprung disease (HSCR, OMIM 142623), a developmen-
tal disorder occurring in 1 of 5,000 live births, is characterized by
the absence of ganglion cells along variable lengths of the distal
gastrointestinal tract, which results in tonic contraction of the
aganglionic gut segment and functional intestinal obstruction.
Such aganglionosis is attributed to a failure of neural crest cells to
migrate, proliferate, and/or differentiate during enteric nervous
system (ENS) development in the embryonic stage [1,2]. HSCR
most commonly presents as isolated cases and displays a complex
pattern of inheritance with low, sex dependent penetrance and
variable expression.
The RET proto-oncogene (OMIM 164761) is the major gene
associated to HSCR with differential contributions of its rare and
common, coding and noncoding mutations to the multifactorial
nature of this pathology [3,4]. In addition, numerous molecular
genetic studies have identified rare coding mutations in many
other genes (GDNF, NRTN, PSPN, EDNRB, EDN3, ECE1, NTF3,
NTRK3, SOX10, PHOX2B, L1CAM, ZFHX1B, KIAA1279, TCF4,
PROK1, PROKR1, PROKR2 and NRG1) related to HSCR [2,3,5–
9]. However, cumulatively, the conventional mutations related to
HSCR reported so far explain less than 5% of cases, being the vast
majority of them long segment HSCR/total colonic aganglionosis
(L-HSCR/TCA) and syndromic forms of the disease.
HSCR is regarded as a complex and multifactorial disorder, in
which the contribution of several different loci acting in an
additive or multiplicative manner is usually required to cause the
disease [3]. Because of this evidence, many different techniques
have emerged to identify new HSCR susceptibility loci, such as
genome wide linkage and genome wide association studies (GWLS
and GWAS respectively) [10,11]. In this way, several HSCR-
associated regions, such as 16q23 [10], 21q21 [11], 9q31 [12],
19q12 [13], 3p21 [13,14] or 4q31.3-q32.3 [15] have been
described, although the genes underlying such associations have
not been identified yet in the majority of the cases.
A recent GWAS has successfully identified NRG1 as a new
candidate gene for HSCR [16]. To refine the locus on 8p12 that
had resulted to be linked [16], a total of 243 SNPs were genotyped
in Chinese HSCR patients and controls [17]. Genotype analysis
narrowed down the HSCR-associated region to six of the most
associated SNPs (rs16879552, rs7835688, rs10088313,
rs10094655, rs4624987 and rs3884552) mapping to the NRG1
promoter. Moreover, significant differences in NRG1 expression
levels between patients and controls bearing the same rs10088313
risk genotype were detected [17]. This seems to indicate that the
effects of NRG1 common variants are likely to depend on other
alleles or epigenetic factors present in patients and would account
among other factors for the variability in the genetic predisposition
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demonstrated through the identification of coding mutations
whose pathogenic role was demonstrated by different functional
approaches [8]. In such study, the authors also reported the
expression of NRG1 and its receptors in gut, although only NRG1
type I HRG-ß1 (NM_013956.2) was detected in HSCR and
control guts but no isoforms type II or III.
A recent study, using TaqMan single-nucleotide polymorphism
genotyping and PCR-restriction fragment length polymorphism,
to validate the association of the RET-protooncogene and the
NRG1 in HSCR in Thai sporadic HSCR cases, has been reported.
The rs2435357 (RET-protooncogene) and rs2439305 (NRG1)
showed the strongest associations with the disease. They concluded
that the genetic variation of the RET-protooncogene and NRG1 is
involved in the risk of HSCR development in the Thai population.
Moreover, the study also detected a combined effect of SNPs by
SNP-SNP interaction, which may help in predicting HSCR risk
[18].
NRG1 is a trophic factor that contains an epidermal growth
factor (EGF)-like domain that signals by stimulating ErbB receptor
tyrosine kinases. Most NRG1 isoforms are synthesized as
membrane-anchored precursors called pro-NRG1s that are
subsequently, cleavaged to be released into the extracellular
medium, where they can act by activating ErbB-mediated
pathways. The NRG1 type I isoforms present a single hydropho-
bic sequence that crosses the plasma membrane, leaving exposed
on the surface the EGF module and the other domains that are in
N-terminal position, as immunoglobulin (Ig-like) domain
[19,20,21,22]. This area is flanked by basic amino acid sequences
which could act as anchor sequences and control that the topology
of the molecule is correct [21]. It has been proposed that the
transmembrane sequence of the NRG1 could act as a signal
peptide controlling its association with membranes and its entry
into the signalling pathway since, as mentioned above, these
molecules have a consensus sequence at its N-terminal to carry out
this function [23,24]. The signal triggered by the union of NRG
proteins with their ErbB receptors affect some cellular processes as
proliferation, differentiation, migration, apoptosis and cellular
survival [25–27]. It has been previously described that NRG1
receptors ErbB2/ErbB3 are expressed in mouse vagal neural crest
cells entering the developing gut and in adult intestinal epithelia of
both humans and mice [28–31]. In addition, NRG1 is also
expressed in mice and human intestinal mucosa and enteric
ganglia [32,33]. The loss of ErbB2 signalling in the colonic
epithelial cells in mice led to postnatal colonic aganglionosis
because in absence of that receptor the production of survival
factors required for the postnatal maintenance of the ENS could
not be induced by NRG1 [34].
The genetic and functional evidence for a role of NRG1 in ENS
and more specifically in HSCR [8,29,35], led us to perform a
complete evaluation of this gene in the context of this disease in a
series of Spanish patients.
Materials and Methods
Patients and Controls Subjects
In this study we have included a total of 207 Spanish HSCR
patients (23% female, 77% male), and their parents when
available. 188 were sporadic cases, while 19 were familial cases
belonging to 13 different families. In addition, we also analyzed a
group of 150 normal controls comprising unselected, unrelated,
race, age, and sex-matched individuals.
A written informed consent was obtained from all the
participants for clinical and molecular genetic studies. The study
was approved by the Ethics Committee for clinical research in the
University Hospital Virgen del Rocı ´o (Seville, Spain) and complies
with the tenets of the declaration of Helsinki.
Mutational Analysis
Genomic DNA was extracted from peripheral blood leukocytes
from all the individuals included in the study, using standard
protocols.
The mutational screening of the complete coding sequence of
NRG1 (HRGß1 isoform) was carried out by denaturing high-
performance liquid chromatography in a WAVE DNA Fragment
Analysis system (Transgenomic). Those fragments with aberrant
profiles were subjected to sequence analysis (NRG1
NM_013956.3) using an ABI PrismH3730 Genetic Analyzer and
the SeqScapeH v2.5 software (Applied Biosystems).
When a novel change was detected, the appropriate DNA
fragment was also screened in a group of 150 normal controls, in
order to determine if the variant was a common polymorphism.
Moreover, parental DNA, when available, was used to perform
the segregation analysis of the identified variants.
To predict the putative pathogenic role of the novel variants at
the protein sequence level, we selected the SIFT and Polyphen
tools (http://blocks.fhcrc.org/sift/SIFT.html; http://genetics.
bwh.harvard.edu/pph/).
Novel variants located within the non-coding region were
submitted to several Splice Sites and Transcription Factors




The NRG1 protein sequences were submitted to ScanProsite
(http://expasy.org/tools/scanprosite/) to scan for the occurrence
of patterns, profiles and motifs stored in the PROSITE database.
Large Scale Genotyping
Three tag SNPs were analyzed in our 134 HSCR trios and
controls using TaqmanH technology, in a 7500 Fast Real-Time
PCR System (Applied Biosystems) (conditions available upon
request). They had been previously described as associated with
HSCR [rs16879552 C.T; rs7835688 C.G and rs10088313
G.T] in the Chinese population [16,17]. For each polymor-
phism, deviation of the genotype frequencies from those expected
under Hardy-Weinberg equilibrium was assessed. Allelic and
genotypic frequency and distribution of the three polymorphisms
were calculated and then compared between patients and controls.
Moreover, parental haplotypes were constructed as previously
described [36] in the context of the affected children’s haplotypes,
so that transmitted and non-transmitted haplotypes from unaf-
fected parents to affected children were noted and their
frequencies compared.
Generation of Mutated Constructs
Full-length human NRG1 cDNA (NRG-1 NM_013956.3)
subcloned into a pFLAG-CMV expression vector was provided
by Garcia-Barcelo MM (Hong Kong, China). The mutations
M139I, M111T and R438H were generated through PCR-
mediated site-directed mutagenesis (Quick-Change XL site-
directed mutagenesis kit (Stratagene) and confirmed by direct
sequencing.
New Mutations in NRG1 Gene Related with HSCR
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COS-7 cells were obtained from ATCC (CRL-1651) and
maintained in DMEM medium containing 10% FBS, penicillin/
streptomycin and L-glutamine (Invitrogen).
For expression studies by immunoblotting, 8 mg of plasmids
carrying wild-type (wt) or mutant (mt) NRG-1 cDNAs were
transiently transfected into 4610
5 COS-7 cells (100 mm dishes)
using FuGene (Promega) following manufacturer’s instructions.
Cells and conditioned medium were collected 24 hours after
transient transfection and used for the subsequent experiments.
We obtained a transfection efficiency around 80%.
Western Blotting
Cells from three 100 mm dishes were collected and then lysed
with cell lysis buffer (20 mM TrisHCl pH 8.0, 135 mM NaCl,
1 mM EDTA, 1.5 mM MgCl2, 1% Triton X-100, 10% glycerol
and a cocktail of proteases inhibitors). In addition, conditioned
medium was collected, filtered through 0.2 mm pore size sterile
filter unit (Millipore) and then concentrated up to 30 folds by
centrifugation through an Amicon-10 K (Millipore) concentrator.
Protein concentrations were estimated using the Bradford (Bio-
Rad) assay with bovine serum albumin as a standard.
Thirty mg of proteins obtained from cell extracts and 100 mg
from conditioned media were separated by SDS–PAGE on 10%
polyacrilamide gels, transferred onto polyvinylidene difluoride
membranes (Hybond, GE Healthcare) and probed with primary
antibodies overnight at 4uC. A rabbit polyclonal anti-NRG1
(1:2000; F20, Santa Cruz Biotechnology) and a rabbit polyclonal
anti-FLAG M2 (1:10000, Sigma Aldrich) were used as primary
antibodies.
Membranes were washed and incubated with secondary
antibody anti-rabbit HRP-conjugated (1:7000; Cell Signalling)
for 90 min at room temperature, followed by detection using ECL
reagents (GE Healthcare). The same membranes were stripped
with stripping buffer (100 mM 2-mercaptoethanol, 2% sodium
dodecyl sulfate, 62.5 mM Tris–HCl, pH 6.7), blocked and
reprobed with monoclonal antibody anti-a-tubulin (1:5000; Sigma
Aldrich) to ensure equal loading of cell protein per lane.
The representative pictures of at least three independent assays
were analyzed. The bands were scanned and quantified by
Quantity One software (Bio-Rad). The results were corrected for
background values and normalized and expressed relative to the
internal control, a-tubulin. Data were analyzed using the paired
Student’s t test. A p value,0.05 was interpreted to represent a
statistically significant difference.
Immunocytochemistry
Twenty-four hours after the transient transfection with 2 mg
each DNA onto 6-well plates, the transfected cells were fixed with
4% paraformaldehyde. Expression of the protein was monitored
by immunostaining with rabbit polyclonal anti-NRG-1 (F20,
1:5,000, Sigma-Aldrich). After washing, the immunosignals were
then detected using the secondary antibody conjugated with Texas
red (1:200; Alexa 568, Invitrogen). All cultures were counter-
stained with DAPI to detect nuclei. Cells were photographed using
an Olympus BX61 microscope with a digital camera DP72 under
fluorescence illumination (Olympus Espan ˜a, S.A.U.).
Results
Analysis of NRG1 Variants and Haplotypes
We conducted a case-control association study to discern
whether any of the variants were directly related to the HSCR
phenotype in our population. Allelic and genotypic frequencies
and distribution of the NRG1 polymorphisms showed no
statistically significant differences in patients versus controls
(Table 1). Similarly, no significant differences were obtained in
the comparison of transmitted versus non transmitted alleles or
haplotypes of NRG1 from healthy parents to their affected children
(data not shown).
Mutational Analysis
The screening of the coding regions of NRG1 (HRGß1) gene in
our cohort of 207 Spanish HSCR patients revealed 18 variants
(Table 2), nine of them were located within the non-coding region.
After the bioinformatic predictions, we failed to find that any of
Table 1. Allelic distribution and frequency of NRG1
genotyped variants.
Variant Allele HSCR (%) Controls (%)
rs16879552 C.T C 267 (99.6%) 262 (97.8%)
T 1 (0.4%) 6 (2.2%)
c
2=2.32, p=0.123
rs7835688 C.G C 131 (48.8%) 114 (42.5%)
G 137 (51.2%) 154 (57.5%)
C
2=2.17, p=0.140
rs10088313 G.T G 265 (98.9%) 263 (98.1%)
T 3 (1.1%) 5 (1.9%)
c
2=0.13, p=0.725
Allelic distribution and frequency of the NRG1 genotyped variants in HSCR
patients and controls and their statistical comparison through c
2.
doi:10.1371/journal.pone.0036524.t001
Table 2. Sequence variants detected in our cohort of HSCR
patients.
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Compilation of all the sequence variants obtained through our genetic
analyses.
doi:10.1371/journal.pone.0036524.t002
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formation or modification of a transcription factor binding site in
the DNA sequence.
Regarding the coding region, three out of the remaining nine
variants (M111T, M139I, R438H) were novel variants and were
absent in the 150 controls tested (Table 3). We checked the 1000
Genomes Project, the NCBI and dbSNP databases and Ensembl
for the presence of the variants identified in our HSCR patients
and none were previously described.
It is worthy to mention that the M111T variant was present in
three patients and two of them also harbour the A373V RET
mutation previously associated with HSCR. In addition, M139I
was a de novo variant present only in one patient (Table 2).
Based on bioinformatic predictions (http://prosite.expasy.org/;
http://emboss.bioinformatics.nl/cgi-bin/emboss/garnier), none
of the three variants studied affected the transmembrane domain,
although all of them affected functional domains of the wild-type
protein (Figure 1). In addition, based on Polyphen and SIFT tools
as indicators of functional relevance, M111T and R438H were
predicted to be probably damaging. Although M139I was
predicted to be benign, it was a de novo variant and therefore we
perform to in vitro methods to further discern pathogenic effect in
these three new variants (Table 2).
The location of the affected residues in the NRG1 protein
(M111T in the Ig-like domain, M139I flanking the EGF-like
domain and R438H in the cytoplasmic domain) (Figure 1) suggests
that M111T may affect the stability of the protein on the
extracellular domain and that M139I could affect the receptor
activation of the NRG1 protein. As well as our R438H mutant
protein, it has been previously reported that a NRG1 variant
located at the cytoplasmic domain, would affect the proteolytic
cleavage of the pro-NRG1 protein [8].
Therefore, we decided to analyze if any of M111T, M139I and
R438H variants would affect the quantity of NRG1 normal
protein both at total cell lysates and at concentrated conditioned
media based on the type of processing of this type of proteins.
Both wt and mt proteins were generated to subsequently study
the levels and cellular location of the NRG1 proteins. Immuno-
blotting assays performed with whole cell lysates showed a
significant reduction (M111T p=0,0019; M139I p=0,0012;
R438H p=0,0026) on the total quantity of the three mutant
proteins (M111T, M139I and R438H) in comparison with the wt
protein (Figure 2A and 2B). Reduced amount of these NRG1
mutant proteins would suggest alteration of the signalling
pathways regulated by NRG1, although further experiments are
required to discern this hypothesis. In order to check the
modifications on the cleavage processes for the variants tested,
we have performed immunoblotting with conditioned media of
each sample but any significant alteration was detected (Figure 2C
and 2D).
Immunocytochemistry revealed a different distribution of the wt
and mt NRG1 proteins in the cytoplasmic organelles, suggesting
that all three mt affect the NRG1 protein distribution or location.
We could observe a typical punctuate pattern for the wt protein,
corresponding to a protein anchored to the cytoplasmic mem-
brane, although the three mt proteins showed a patchier and
perinuclear distribution, which showed a different distribution in
comparison with the wt protein (Figure 3).
Discussion
In the present study we have performed a mutational screening
and analysis of common sequence variants on the NRG1 gene in a
Spanish cohort of HSCR patients.
We did not find any significant difference after comparing allelic
and genotypic frequencies of the NRG1 polymorphisms analysed in
HSCR vs controls. These results are not concordant with those
previously described in the Chinese population, in which a clear
over-representation of the three variants was found in the HSCR
Table 3. Candidate variants detected in HSCR patients.
Nucleotide change Amino Acid change In silico prediction LS Inheritance Other
c.332T.C p.M111T Probably damaging S-HSCR Father RET: A373V
S-HSCR Father RET: A373V
S-HSCR Mother –
c.417G.A p.M139I Benign S-HSCR De novo –
c.1313G.A p.R438H Probably damaging S-HSCR NA –
S-HSCR NA –
List of details of the candidate variants in NRG1 isoform ß1 to be mutations associated with HSCR phenotype analyzed.
*NA: Not available.
LS=Length segment.
Other=Mutations in other genes.
doi:10.1371/journal.pone.0036524.t003
Figure 1. Mutant NRG1 proteins. Scheme of the main regions of
NRG1 isoform ß1 protein and the location of the three variants
analyzed.
doi:10.1371/journal.pone.0036524.g001
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disease is restricted to such specific population. In fact the existence
ofothergeneticfactorsconferringsusceptibilitytoHSCRinspecific
populations has been repeatedly reported. For instance, it has been
reported that there exist two different RET haplotypes encompass-
ing the enhancer mutation that are over-transmitted to the HSCR
offspring in Caucasian populations (Spanish, Italian, French, and
Dutch), while in the Chinese sample only one of those haplotypes
was present [3]. A possible explanation was that the enhancer
mutation arose on one haplotype which, after the Asian-European
split, rearranged to give also the other haplotype, but exclusively in
the European part. A similar hypothesis could be forwarded to
explain the NRG1 effects in the Chinese population, being this
supported by the fact that great differences are observed among the
frequencies of the studied variants between both populations
(rs16879552 Spanish=0,4%–2,2% vs Chinese=38%–51%; rs
7835688 Spanish=51,2%–57,5% vs Chinese=15%–26%; rs
10088313 Spanish=1,1%–1,9% vs Chinese=40–52%). That
difference among Caucasian and Asian populations had been
recently corroborated by a recent genotyping study in Thai
population, where the genetic variation of the RET-protooncogene
and NRG1 is involved in the risk of HSCR development in the Thai
population [18].
Previous studies had indicated that NRG1 is a signalling protein
that mediates cell-cell interactions and it is essential for the
development and function of multiple organ systems and its
dysregulation has been linked to diseases such as breast cancer,
schizophrenia and HSCR [8,29,37]. In addition, it has been
shown that not only common, but also rare variants of the NRG1
gene contribute to HSCR [8]. Here we report some novel variants
located within the non-coding region although after bioinformatic
predictions we failed to find that any of those variants would affect
neither the splicing process nor the formation or modification of a
transcription factor binding site in the DNA sequence. Further-
more, we report three new missense mutations (M111T, M139I
and R438H) as probably causing mutations for HSCR. Those
variants were located on functional domains within the protein
and all of them were found totally absent in control population.
After functional approaches, we found that M111T, R438H and
M139I mutant proteins induced a significant reduction in the
quantity of the normal NRG1 protein levels in cells expressing
them. In fact, our in silico predictions revealed that M111T and
R438H would be probably damaging. Two of the affected residues
in the NRG1 protein were located at the extracellular domain
(M111T was in the Ig-like domain and M139I was in the EGF
domain) and the other one, R438H, was located at the cytoplasmic
domain. The Ig-like domain in NRGs proteins could act in the
process of attenuation of signalling through ErbB receptors,
promoting the internalization and degradation of the complex
ligand-receptor. This could be a control mechanism of the NRGs
biological activity limiting their ability to diffuse freely and
allowing the intracellular accumulation of these proteins to act
quickly after being processed. The variant M111T detected at this
domain would influence this process of attenuation which would
explain the significant reduction of NRG1 level detected in cell
lysates and the absence of differences obtained in the conditioned
media. In addition, there are two important facts to mention about
M111T variant: First, the change of a methionine by a threonine
Figure 2. Immunoblot analysis of NRG1 mutants. Human NRG1 wildtype (WT) and mutants (M111T, M139I and R438H) were overexpressed in
COS7 cell line. A) The intracellular levels of NRG1 wild-type and M111T, M139I and R438H mutants were detected with anti-neuregulin 1a/ß1/2 (F-20)
antibody. All three mutants showed a significant lower protein expression. Alpha-tubulin was used as the loading control for normalization. B) The
bar chart represents the quantitative data of the relative protein expression levels normalized with alpha-tubulin in three independent assays.
(**p,0.005). C) The release of the extracellular domain in the medium was detected using anti-FLAG M2 antibody. The mutations did not affect the
release of that domain of the NRG-1 protein. D) The bar chart represents the quantitative data of the relative protein expression levels normalized in
three independent assays.
doi:10.1371/journal.pone.0036524.g002
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change would alter structures and/or functions of NRG1 protein,
as we can guess by functional approaches. Secondly, the A373V
RET mutation was also present in two out of three patients with
this NRG1 mutation, both with paternal inheritance. Both patients
have the A373V RET mutation with maternal inheritance. The
NRG1 and RET loci would act in an additive manner, which could
be a relevant key to understand the genetic architecture and gene
networks underlying this complex trait. Our findings would
completely fit with the additive model of inheritance previously
proposed for HSCR in which the expression of the disease seems
to depend on the contribution of different combinations of gene
alleles acting in an additive or multiplicative fashion [3].
Regarding the variant M139I contained in the EGF domain,
which is needed and sufficient to induce the receptor activation
[19], it induces a significant reduction of the total NRG1 protein
levels. Based on previous reports [8], we would suggest that this
alteration could modify the receptor activation, which means
functionality of the normal NRG1 protein. Regarding the R438H,
it is known that the cytoplasmic domain regulates the proteolytic
release of its extracellular domain in a sequence specific manner
[38,39]. This fact, together with the reported variant also located
at this domain [8], lead us to speculate that R438H would affect
the proteolytic cleavage of the pro-NRG1 protein.
In addition, the NRG1 receptor ErbB3, which is essential for
neural crest cell survival, is regulated by Sox10 [29,40,41].
Therefore, as previously hypothesized [8] it would be plausible to
speculate that reduced levels of NRG1 protein, observed in all
three new variants, would affect the Sox10-mediated maintenance
of ENS progenitors and contribute to the aganglionosis associated
to HSCR disease.
In summary, the above mentioned results constitute the first
report of NRG1 mutations related to HSCR patients in a
Caucasian population. These results are in accordance with the
additive model previously proposed for HSCR [3], so we could
hypothesize that these three novel variants, M111T, M139I and
R438H would have functional consequences during embryonic
development, probably being causing mutations which contribute
to HSCR.
The delineation of NRG1 function holds great promise for our
understanding of the molecular pathways underlying HSCR.
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